Stakeholders offer input on educational materials for rare disease drug development
Regulatory NewsJeff Craven
Biologics/ biosimilars/ vaccinesNorth AmericaPharmaceuticalsProduct LifecycleRegulatory NewsJeff CravenBiologics/ biosimilars/ vaccinesNorth AmericaPharmaceuticalsProduct Lifecycle